Showing results (1-10 of 167) with videos related to
Sort By:
Pageof 17
Pharmacotherapy|May 14, 2003
Variability in polyene content and cellular toxicity among deoxycholate amphotericin B formulationsJohn D Cleary, P David Rogers, Stanley W ChapmanThe Annals of Pharmacotherapy|March 18, 2003
Voriconazole: a new triazole antifungal agentMargaret M Pearson, P David Rogers, John D Cleary, et al.Pharmacotherapy|August 19, 2003
Effects of amphotericin B and caspofungin on histamine expressionJohn D Cleary, Michael Schwartz, P David Rogers, et al.The Journal of Antimicrobial Chemotherapy|December 4, 2002
Differential expression of genes encoding immunomodulatory proteins in response to amphotericin B in human mononuclear cells identified by cDNA microarray analysisP David Rogers, Margaret M Pearson, John D Cleary, et al.Transactions of the American Clinical and Climatological Association|July 4, 2008
In search of the holy grail of antifungal therapyStanley W Chapman, Donna C Sullivan, John D ClearyThe Journal of Antimicrobial Chemotherapy|October 9, 2007
High purity amphotericin BJohn D Cleary, Stanley W Chapman, Edwin Swiatlo, et al.Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|August 30, 2008
Association between Histoplasma exposure and strokeJohn D Cleary, Margaret Pearson, Jake Oliver, et al.Antimicrobial Agents and Chemotherapy|April 2, 2008
Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatmentJohn D Cleary, Guillermo Garcia-Effron, Stanley W Chapman, et al.Medical Mycology|January 31, 2009
The interaction of mannose binding lectin (MBL) with mannose containing glycopeptides and the resultant potential impact on invasive fungal infectionPatricia I Sealy, Bianca Garner, Ed Swiatlo, et al.The American Journal of the Medical Sciences|June 16, 2007
Single low-dose mebendazole administered quarterly for ascaris treatmentJohn D Cleary, Devon Graham, William B Lushbaugh, et al.Pageof 17